Pharmacokinetic Variability — MCQs
A factor that is likely to increase the duration of action of a drug that is partially metabolized by CYP3A4 in the liver is:
A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?
Drug X has an affinity for albumin, while drug Y has 150 times greater affinity. Which of the following statements is MOST accurate?
Which of the following statements about warfarin is false?
At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?
Which of the following statements represents the most clinically significant aspect of drug metabolism?
In which phase of clinical trials is drug dosing typically determined?
In which of the following conditions is digoxin most likely to accumulate to toxic levels?
Cisapride was withdrawn from the market due to?
Which one of the following drugs has a narrow therapeutic range?
Pharmacokinetic Variability Indian Medical PG Practice Questions and MCQs
Question 1: A factor that is likely to increase the duration of action of a drug that is partially metabolized by CYP3A4 in the liver is:
- A. Chronic administration of phenobarbital with the drug
- B. Displacement from tissue binding sites by another drug
- C. Chronic administration of rifampicin
- D. Chronic administration of cimetidine with the drug (Correct Answer)
Explanation: ***Chronic administration of cimetidine with the drug*** - **Cimetidine** is a potent inhibitor of various **cytochrome P450 (CYP450) enzymes**, including **CYP3A4**. - By inhibiting the metabolism of a drug predominantly metabolized by **CYP3A4**, cimetidine will increase its plasma concentration and extend its **duration of action**. *Chronic administration of phenobarbital with the drug* - **Phenobarbital** is a strong **inducer of CYP450 enzymes**, including **CYP3A4**. - Induction would accelerate the metabolism of the drug, thus **decreasing its duration of action**, not increasing it. *Displacement from tissue binding sites by another drug* - Displacement from tissue binding sites would primarily increase the **free fraction of the drug in the plasma**, leading to a more rapid distribution to eliminating organs and potentially **shorter duration of action** if elimination is extraction-limited. - This mechanism does not directly impact the **metabolic rate** unless clearance is significantly altered through increased availability for metabolism. *Chronic administration of rifampicin* - **Rifampicin** is a potent **inducer of CYP3A4** and other CYP enzymes. - Its administration would lead to **increased metabolism** of the co-administered drug, thereby **reducing its duration of action**.
Question 2: A patient on digoxin therapy presents with atrial fibrillation and controlled ventricular rate. Upon evaluation, the patient's serum digoxin levels are elevated compared to previous values. Which of the following concomitant medications is most likely to have contributed to the enhanced digoxin toxicity?
- A. Triamterene
- B. KCL
- C. Atenolol
- D. Clarithromycin (Correct Answer)
- E. Amiodarone
Explanation: ***Clarithromycin*** - **Clarithromycin** is a **macrolide antibiotic** known to inhibit the cytochrome P450 3A4 (CYP3A4) enzyme system and **P-glycoprotein**. - This inhibition leads to decreased metabolism and **efflux of digoxin**, resulting in **increased serum digoxin levels** and enhanced toxicity. - Among the options, clarithromycin is the **most common cause** of elevated digoxin levels through P-gp inhibition. *Triamterene* - **Triamterene** is a **potassium-sparing diuretic** that can increase serum potassium. - **Hyperkalemia** generally *reduces* the binding of digoxin to Na+/K+-ATPase, thereby potentially *reducing* its toxic effects. - Does not significantly affect digoxin serum levels. *KCL* - **Potassium chloride (KCl)** is used to correct **hypokalemia**. - **Hypokalemia** can *potentiate* digoxin toxicity because low potassium increases digoxin binding to the Na+/K+-ATPase pump. - However, KCl supplementation *corrects* hypokalemia and would actually *reduce* toxicity risk, not increase serum digoxin levels. *Atenolol* - **Atenolol** is a **beta-blocker** primarily used to control heart rate and blood pressure. - While it can slow the heart rate like digoxin (additive pharmacodynamic effect), it does not significantly alter the **pharmacokinetics** or serum levels of digoxin. *Amiodarone* - **Amiodarone** is an **antiarrhythmic** that can inhibit P-glycoprotein and increase digoxin levels. - However, in this scenario, **clarithromycin** is more commonly associated with acute elevations in digoxin levels in clinical practice. - Amiodarone interactions are well-known and typically require dose adjustments at initiation.
Question 3: Drug X has an affinity for albumin, while drug Y has 150 times greater affinity. Which of the following statements is MOST accurate?
- A. Drug X will be more available in tissues
- B. Drug Y will be less available in tissues
- C. Toxicity of drug Y may be influenced by multiple factors, not just its binding.
- D. The free concentration of drug X in blood is higher, facilitating tissue distribution. (Correct Answer)
Explanation: ***Correct: The free concentration of drug X in blood is higher, facilitating tissue distribution.*** - This is the **MOST accurate and complete** answer because it directly addresses the pharmacokinetic mechanism - Drug X has **lower affinity for albumin** → larger proportion remains **unbound (free)** in plasma - Only **free (unbound) drug** can cross capillary membranes to distribute into tissues - This statement precisely explains both the **cause** (higher free concentration) and **effect** (facilitating tissue distribution) *Drug X will be more available in tissues* - This statement is **factually true** and follows logically from drug X's lower protein binding - However, it's **less precise** than the correct answer because it doesn't explicitly explain the **mechanism** (higher free concentration) - The term "available" is less specific than "free concentration," which is the key pharmacokinetic parameter *Drug Y will be less available in tissues* - This statement is also **factually true** - drug Y's **150× higher albumin affinity** means more drug is bound - Higher protein binding → **smaller free fraction** → less tissue distribution - However, like option 1, this doesn't explicitly state the **mechanistic principle** involving free drug concentration - The question asks for the MOST accurate statement, and this focuses on drug Y rather than explaining the core concept *Toxicity of drug Y may be influenced by multiple factors, not just its binding* - While this is a **true general principle**, it's **not directly relevant** to the specific question - This statement doesn't address the **pharmacokinetic implications** of differential albumin binding - It's too vague and doesn't demonstrate understanding of the relationship between protein binding and tissue distribution - The question specifically asks about the affinity differences and their consequences
Question 4: Which of the following statements about warfarin is false?
- A. Half-life is 25 to 60 hours
- B. Inhibits vitamin K dependent clotting factor synthesis
- C. Warfarin does not cross the placenta (Correct Answer)
- D. Contraindicated in patients with severe hepatic failure
Explanation: ***Warfarin does not cross the placenta*** - Warfarin **rapidly crosses the placenta**, leading to fetal exposure and potential teratogenic effects, such as **fetal warfarin syndrome**. - This characteristic makes warfarin generally **contraindicated during pregnancy**, especially in the first trimester. *Half-life is 25 to 60 hours* - The half-life of warfarin is indeed relatively long, ranging from approximately **25 to 60 hours**, which contributes to its once-daily dosing. - This prolonged half-life means that changes in dosing take several days to reach a **new steady-state** and affect the International Normalized Ratio (INR). *Inhibits vitamin K dependent clotting factor synthesis* - Warfarin functions as a **vitamin K antagonist**, inhibiting the hepatic synthesis of vitamin K-dependent clotting factors **II, VII, IX, and X**. - It achieves this by blocking **vitamin K epoxide reductase**, an enzyme essential for reactivating vitamin K. *Contraindicated in patients with severe hepatic failure* - Warfarin is primarily metabolized in the **liver** by cytochrome P450 enzymes, and its clotting factors are synthesized in the liver. - Therefore, **severe hepatic failure** can impair both warfarin metabolism and the production of clotting factors, leading to an increased risk of bleeding and making it a contraindication.
Question 5: At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?
- A. Absorption of drug is 50% ionic and 50% non-ionic
- B. Conc. of drug is 25% ionic and 75% non-ionic
- C. Conc. of drug is 75% ionic and 25% non-ionic
- D. Conc. of drug is 50% ionic and 50% non-ionic (Correct Answer)
Explanation: ***Conc. of drug is 50% ionic and 50% non-ionic*** - At **pKa = pH**, the concentrations of the **ionized** and **unionized** forms of a drug are equal as per the **Henderson-Hasselbalch equation**. - This means that exactly **half** of the drug molecules are in their charged (ionic) state, and the other half are in their uncharged (non-ionic) state. *Absorption of drug is 50% ionic and 50% non-ionic* - The amount of drug that is absorbed is dependent on the **non-ionic concentration** available at the absorption site, but this option incorrectly states that the *absorption itself* is 50% ionic. - Absorption primarily occurs for the **non-ionic, lipophilic form** as it can more readily cross cell membranes. *Conc. of drug is 75% ionic and 25% non-ionic* - This ratio would occur when the **pH** is either 0.5 units above the pKa for a weak acid or 0.5 units below the pKa for a weak base. - For example, if **pH = pKa + 0.5** (for a weak acid), approximately 75% would be ionic. *Conc. of drug is 25% ionic and 75% non-ionic* - This ratio would occur when the **pH** is either 0.5 units below the pKa for a weak acid or 0.5 units above the pKa for a weak base. - For example, if **pH = pKa - 0.5** (for a weak acid), approximately 25% would be ionic.
Question 6: Which of the following statements represents the most clinically significant aspect of drug metabolism?
- A. Most common enzyme involved is CYP 3A4/5 (Correct Answer)
- B. Glucuronidation is a phase II reaction
- C. Reduction is a phase I reaction
- D. Cytochrome P450 is involved in phase I reactions
Explanation: ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.
Question 7: In which phase of clinical trials is drug dosing typically determined?
- A. Phase 1 (Correct Answer)
- B. Phase 2
- C. Phase 3
- D. Phase 4
- E. Phase 0
Explanation: ***Phase 1*** - This phase involves a small group of **healthy volunteers** to assess the drug's safety, **pharmacokinetics (PK)**, and establish an initial dosing range. - The primary goal is to determine a **safe dosage level**, establish the **maximum tolerated dose (MTD)**, and identify potential side effects. - This is where drug dosing is **typically determined**. *Phase 0* - This is an exploratory phase involving **microdosing** studies with subtherapeutic doses. - The goal is to gather preliminary PK/PD data, but **not to determine therapeutic dosing**. *Phase 2* - This phase involves a larger group of **patients** with the condition to be treated. - The main goal is to evaluate the drug's **effectiveness** and further assess safety, but not primarily to determine initial dosing. *Phase 3* - This phase involves a large number of patients across multiple sites to confirm the drug's **efficacy** and monitor side effects in a broader population. - Dosing strategies have generally been established in earlier phases, and this phase primarily validates them. *Phase 4* - This phase occurs **after a drug has been approved** and marketed. - It involves ongoing surveillance to monitor long-term effects, collect additional information on safety, and identify new uses, but not initial dose determination.
Question 8: In which of the following conditions is digoxin most likely to accumulate to toxic levels?
- A. Renal insufficiency (Correct Answer)
- B. Chronic hepatitis
- C. Advanced cirrhosis
- D. Chronic pancreatitis
Explanation: ***Renal insufficiency*** - **Digoxin** is primarily excreted unchanged by the **kidneys**, so impaired renal function significantly prolongs its half-life and leads to drug accumulation. - Patients with kidney failure require **dose adjustments** or closer monitoring of **digoxin levels** to prevent toxicity. *Chronic hepatitis* - **Chronic hepatitis** primarily affects the **liver's metabolic capacity**, which is not the primary route of **digoxin elimination**. - While severe hepatic dysfunction can subtly impact drug disposition, it's not the main reason for **digoxin accumulation** like **renal insufficiency**. *Advanced cirrhosis* - **Advanced cirrhosis** involves severe liver dysfunction, which can alter drug metabolism and protein binding. - However, **digoxin's elimination** is mainly renal, so liver disease alone does not typically lead to significant accumulation unless accompanied by **renal impairment**. *Chronic pancreatitis* - **Chronic pancreatitis** is a disorder of the pancreas and does not directly impact the **excretion or metabolism** of **digoxin**. - It would not be expected to cause **digoxin accumulation** to toxic levels.
Question 9: Cisapride was withdrawn from the market due to?
- A. QT Prolongation (Correct Answer)
- B. Hepatotoxicity
- C. Nephrotoxicity
- D. PR interval prolongation
Explanation: ***QT Prolongation*** - Cisapride was withdrawn from the market primarily due to its association with **dose-dependent QT interval prolongation**, which increased the risk of serious ventricular arrhythmias. - This **QT prolongation** could lead to potentially fatal **Torsades de Pointes**, a polymorphic ventricular tachycardia. *PR interval prolongation* - While some medications can affect the PR interval, **cisapride's primary cardiac concern** was specifically related to the QT interval, not the PR interval. - PR interval changes generally indicate issues with **AV nodal conduction**, a different mechanism than that affected by cisapride. *Hepatotoxicity* - Although drug-induced liver injury is a known adverse effect for many medications, **hepatotoxicity was not the primary reason** for cisapride's withdrawal. - The most significant and life-threatening adverse effect was its impact on cardiac repolarization. *Nephrotoxicity* - **Nephrotoxicity (kidney damage)** was not identified as a major or significant adverse effect associated with cisapride that led to its market withdrawal. - The drug's safety profile concerns were focused on its cardiovascular effects.
Question 10: Which one of the following drugs has a narrow therapeutic range?
- A. Propranolol
- B. Phenytoin (Correct Answer)
- C. Piroxicam
- D. Prazosin
Explanation: ***Phenytoin*** - **Phenytoin** has a **narrow therapeutic index**, meaning there is a small difference between the therapeutic and toxic doses. - This necessitates **therapeutic drug monitoring** to ensure effective treatment while avoiding adverse effects like nystagmus, ataxia, or gingival hyperplasia. *Propranolol* - **Propranolol** is a **beta-blocker** used for hypertension, angina, and arrhythmias, generally considered to have a wide therapeutic range. - While dose adjustments are common, routine therapeutic drug monitoring is typically **not required** due to its relatively safe profile at higher doses compared to drugs like phenytoin. *Piroxicam* - **Piroxicam** is a **nonsteroidal anti-inflammatory drug (NSAID)** with a relatively wide therapeutic window. - Its primary concerns are gastrointestinal and renal side effects rather than toxicity from a narrow therapeutic range. *Prazosin* - **Prazosin** is an **alpha-1 adrenergic blocker** used for hypertension and benign prostatic hyperplasia, and it generally has a wide therapeutic range. - The main concern with prazosin is **first-dose phenomenon** (orthostatic hypotension), which is an initial effect rather than toxicity from a narrow therapeutic window.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free